Francesca Colamartini
机构：University of Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria, Misericordia University
发表论文 11 篇 · 总被引 16 次 · h-index 3
代表论文
- Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study (2025 · Cancer Immunology Immunotherapy · 被引 6)
- Emerging Predictive Biomarkers of Immunotherapy Sensitivity in Patients with Non-Small Cell Lung Cancer (2026 · ImmunoTargets and Therapy · 被引 5)
- Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (2023 · Oncology and Therapy · 被引 3)
- Clinicogenomic determinants of early progression on first-line osimertinib in EGFR -mutant NSCLC. (2026 · Journal of Clinical Oncology · 被引 1)
- EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the ‘Rebiopsy on osi’ Study) (2026 · The Oncologist)
- PP01.07: Activity of Bevacizumab Combined With Chemotherapy in Advanced RET-Rearranged Non-Small Cell Lung Cancer (2026 · Journal of Thoracic Oncology)